Threshold Amsler grid as a screening tool for asymptomatic patients on hydroxychloroquine therapy

British Journal of Ophthalmology

Volumn 89, Issue 5, 2005, Pages 569-574

  Almony, A ^b   Garg, S ^b   Peters, R K ^a   Mamet, R ^a   Tsong, J ^c   Shibuya, B ^a   Kitridou, R ^a   Sadun, Alfredo A ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b DOHENY EYE INSTITUTE   (United States)

^c GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMSLER GRID; HYDROXYCHLOROQUINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BULL EYE MACULOPATHY; CONTROLLED STUDY; FEMALE; FILTER; HUMAN; LUMINANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETINA MACULOPATHY; SCREENING TEST;

ADULT; AGED; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; HYDROXYCHLOROQUINE; MALE; MIDDLE AGED; RETINAL DISEASES; SCOTOMA; SENSORY THRESHOLDS; VISION SCREENING; VISUAL ACUITY;

EID: 17644365096     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2004.050120     Document Type: Article

References (19)

1. Wall M, Sadun AA. Threshold Amsler grid testing: cross-polarizing lenses enhance yield. Arch Ophthalmol 1986;104:520-3.
2. Wall M, Collins C, May DR. Low-intensity grids improve sensitivity of Amsler grid testing in diabetic patients without background retinopathy. Ann Ophthalmol 1990;22:96-100.
3. Saadati HG, Sadun AA. Three-dimensional quantification of central visual field defects using the modified threshold Amsler grid test. Presented at Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL May, 1997.
4. Amsler M. L'examen qualitif de la fonction maculaire. Ophthalmologica 1947;114:248-61.
5. Amsler M. Quantitative and qualitative vision. Trans Ophthalmol Soc UK 1949;69:397-410.
6. Easterbrook M. Detection and prevention of maculopathy associated with anti-malarial agents. Int Ophthalmol Clin 1999;39:49-57.
7. Ruiz RS, Saatci OA. Chloroquine and hydroxychloroquine retinopathy: how to follow affected patients. Ann Ophthalmol 1991;23:290-1.
8. Fielder A, Graham E, Jones S, et al. Royal College of Ophthalmologists guidelines: ocular toxicity and hydroxychloroquine. Eye 1998;12:907-9.
9. Grierson DJ. Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Ann Rheum Dis 1997;56:188-90.
10. Klippel JH, Stone JH, Crofford L. Primer on the rheumatic diseases. 12th ed. Arthritis Foundation, 2001.
11. Bernstein HN. Ocular safety of hydroxychloroquine. South Med J 1992;85:274-9.
12. Easterbrook M. The ocular safety of hydroxychloroquine. Semin Arth Rhem 1993;23(Suppl 1):62-7.
13. Marmor MF, Carr RE, Easterbrook M, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2002;109:1377-82.
14. Crew SJ. Chloroquine retinopathy with recovery in early stages. Lancet 1964;ii:436-8.
15. Ehrenfeld M, Nesher R, Merin S. Delayed onset of chloroquine retinopathy. Br J Ophthalmol 1986;70:281-3.
16. Sassasni JW, Brucker AJ, Cobbs W, et al. Progressive chloroquine retinopathy. Ann Ophthalmol 1983;15:19-22.
17. Bernstein HN. Ophthalmological considerations and testing in patients receiving long-term antimalarial therapy. Am J Med 1983;75(Suppl):25-34.
18. Ariyasu RG, Lee PP, Linton KP, et al. Sensitivity, specificity, and predictive values of screening tests for eye conditions in a clinic-based population. Ophthalmology 1996;103:1751-60.
19. Schuchard RA. Validity and interpretation of Amsler grid reports. Arch Ophthalmol 1993;111:776-8.